Differential impact of cilostazol on restenosis according to implanted stent type (from a Pooled Analysis of Three DECLARE Randomized Trials)

American Journal of Cardiology

Volumn 112, Issue 9, 2013, Pages 1328-1334

  Lee, Seung Whan ^a   Ahn, Jung Min ^a   Han, Seungbong ^b   Park, Gyung Min ^a   Cho, Young Rak ^a   Lee, Woo Seok ^a   Jang, Jeong Yoon ^a   Kwon, Chang Hee ^a   Lee, Jong Young ^a   Kim, Won Jang ^a   Kang, Soo Jin ^a   Kim, Young Hak ^a   Lee, Cheol Whan ^a   Kim, Jae Joong ^a   Park, Seong Wook ^a   Park, Seung Jung ^a  

^a University of Ulsan   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ADULT; ARTICLE; BOOTSTRAPPING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RISK REDUCTION;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE 3 INHIBITORS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; REPUBLIC OF KOREA; TETRAZOLES; TREATMENT OUTCOME;

EID: 84885950216     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.06.010     Document Type: Article

References (21)

1. J.S. Douglas Jr., D.R. Holmes Jr., D.J. Kereiakes, C.L. Grines, E. Block, Z.M. Ghazzal, D.C. Morris, H. Liberman, K. Parker, C. Jurkovitz, N. Murrah, J. Foster, P. Hyde, G.B. Mancini, W.S. Weintraub, and Cilostazol for Restenosis Trial I Coronary stent restenosis in patients treated with cilostazol Circulation 112 2005 2826 2832
2. S.W. Lee, S.W. Park, Y.H. Kim, S.C. Yun, D.W. Park, C.W. Lee, M.K. Hong, H.S. Kim, J.K. Ko, J.H. Park, J.H. Lee, S.W. Choi, I.W. Seong, Y.H. Cho, N.H. Lee, J.H. Kim, K.J. Chun, S.J. Park, and Investigators DE-LS Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-LONG trial) Am J Cardiol 100 2007 1103 1108
3. S.W. Lee, S.W. Park, Y.H. Kim, S.C. Yun, D.W. Park, C.W. Lee, M.K. Hong, H.S. Kim, J.K. Ko, J.H. Park, J.H. Lee, S.W. Choi, I.W. Seong, Y.H. Cho, N.H. Lee, J.H. Kim, K.J. Chun, and S.J. Park Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients With Diabetes Mellitus: the DECLARE-DIABETES trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients) J Am Coll Cardiol 51 2008 1181 1187
4. S.W. Lee, S.W. Park, Y.H. Kim, S.C. Yun, D.W. Park, C.W. Lee, S.J. Kang, S.J. Park, J.H. Lee, S.W. Choi, I.W. Seong, N.H. Lee, Y.H. Cho, W.Y. Shin, S.J. Lee, S.W. Lee, M.S. Hyon, D.W. Bang, Y.J. Choi, H.S. Kim, B.K. Lee, K. Lee, H.K. Park, C.B. Park, S.G. Lee, M.K. Kim, K.H. Park, W.J. Park DECLARE-LONG II Study Investigators A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients With Long Coronary Lesions) trial J Am Coll Cardiol 57 2011 1264 1270
5. W.K. Laskey, C.W. Yancy, and W.H. Maisel Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8 2006 Circulation 115 2007 2352 2357
6. S.D. Wiviott, E.M. Antman, C.M. Gibson, G. Montalescot, J. Riesmeyer, G. Weerakkody, K.J. Winters, J.W. Warmke, C.H. McCabe, E. Braunwald TRITON-TIMI 38 Investigators Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) Am Heart J 152 2006 627 635
7. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
8. S. Bangalore, S. Kumar, M. Fusaro, N. Amoroso, M.J. Attubato, F. Feit, D.L. Bhatt, and J. Slater Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891
9. S.W. Park, C.W. Lee, H.S. Kim, N.H. Lee, D.Y. Nah, M.K. Hong, J.J. Kim, and S.J. Park Effects of cilostazol on angiographic restenosis after coronary stent placement Am J Cardiol 86 2000 499 503
10. H. Ota, M. Eto, J. Ako, S. Ogawa, K. Iijima, M. Akishita, and Y. Ouchi Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation J Am Coll Cardiol 53 2009 2298 2305
11. G.G. Stefanini, P.W. Serruys, S. Silber, A.A. Khattab, R.J. van Geuns, G. Richardt, P.E. Buszman, H. Kelbaek, A.J. van Boven, S.H. Hofma, A. Linke, V. Klauss, W. Wijns, C. Macaya, P. Garot, C. Di Mario, G. Manoharan, R. Kornowski, T. Ischinger, A.L. Bartorelli, P. Gobbens, and S. Windecker The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) J Am Coll Cardiol 57 2011 2221 2232
12. C. von Birgelen, M.W. Basalus, K. Tandjung, K.G. van Houwelingen, M.G. Stoel, J.H. Louwerenburg, G.C. Linssen, S.A. Said, M.A. Kleijne, H. Sen, M.M. Lowik, J. van der Palen, P.M. Verhorst, and F.H. de Man A randomized controlled trial in second-generation zotarolimus-eluting resolute stents versus everolimus-eluting Xience v stents in real-world patients: the TWENTE trial J Am Coll Cardiol 59 2012 1350 1361
13. S.S. Naidu, M.W. Krucoff, D.R. Rutledge, V.W. Mao, W. Zhao, Q. Zheng, O. Wilburn, K. Sudhir, C. Simonton, and J.B. Hermiller Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after Xience V implantation: results from the 8,061-patient Xience V United States study JACC Cardiovascular interventions 5 2012 626 635
14. S. Massberg, R.A. Byrne, A. Kastrati, S. Schulz, J. Pache, J. Hausleiter, T. Ibrahim, M. Fusaro, I. Ott, A. Schomig, K.L. Laugwitz, J. Mehilli, S. Intracoronary, and Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Investigators Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) trial Circulation 124 2011 624 632
15. C.W. Lee, D.W. Park, K.B. Seung, P.J. Kim, H.J. Park, W.J. Kim, J.Y. Lee, S.J. Kang, S.H. Lee, Y.H. Kim, S.W. Park, and S.J. Park Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions Am J Cardiol 107 2011 990 994
16. M.B. Elam, J. Heckman, J.R. Crouse, D.B. Hunninghake, J.A. Herd, M. Davidson, I.L. Gordon, E.B. Bortey, and W.P. Forbes Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication Arterioscler Thromb Vasc Biol 18 1998 1942 1947
17. K. Watanabe, S. Ikeda, J. Komatsu, S. Inaba, J. Suzuki, S. Sueda, J. Funada, M. Kitakaze, and M. Sekiya Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris Am J Cardiol 92 2003 21 25
18. C.W. Ahn, H.C. Lee, S.W. Park, Y.D. Song, K.B. Huh, S.J. Oh, Y.S. Kim, Y.K. Choi, J.M. Kim, and T.H. Lee Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus Diabetes Res Clin Pract 52 2001 45 53
19. J.H. Lee, G.T. Oh, S.Y. Park, J.H. Choi, J.G. Park, C.D. Kim, W.S. Lee, B.Y. Rhim, Y.W. Shin, and K.W. Hong Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol J Pharmacol Exp Ther 313 2005 502 509
20. Y.H. Jeong, S.W. Lee, B.R. Choi, I.S. Kim, M.K. Seo, C.H. Kwak, J.Y. Hwang, and S.W. Park Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol 53 2009 1101 1109
21. S.W. Lee, S.W. Park, S.C. Yun, Y.H. Kim, D.W. Park, W.J. Kim, J.Y. Lee, C.W. Lee, M.K. Hong, J.J. Kim, and S.J. Park Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Adverse Serious Cardiac Events (DECREASE registry) Am Heart J 159 2010 284 291